HC Wainwright Expects Stronger Earnings for Pyxis Oncology

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Stock analysts at HC Wainwright lifted their Q1 2025 earnings per share estimates for shares of Pyxis Oncology in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.29) per share for the quarter, up from their previous estimate of ($0.38). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.17) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at $0.24 EPS.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The firm had revenue of $16.15 million for the quarter.

Separately, Royal Bank of Canada restated an “outperform” rating and set a $8.00 target price on shares of Pyxis Oncology in a research report on Wednesday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Pyxis Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.20.

Pyxis Oncology Stock Up 8.0 %

PYXS stock opened at $1.21 on Friday. The company has a market cap of $74.52 million, a P/E ratio of -1.17 and a beta of 1.11. Pyxis Oncology has a twelve month low of $0.99 and a twelve month high of $6.18. The business has a fifty day moving average of $1.33 and a 200-day moving average of $2.36.

Institutional Investors Weigh In On Pyxis Oncology

A number of institutional investors have recently made changes to their positions in PYXS. Millennium Management LLC grew its stake in shares of Pyxis Oncology by 53.8% during the fourth quarter. Millennium Management LLC now owns 2,980,906 shares of the company’s stock worth $4,650,000 after purchasing an additional 1,043,228 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Pyxis Oncology during the third quarter worth $1,405,000. Ridgeback Capital Investments L.P. acquired a new stake in shares of Pyxis Oncology during the fourth quarter worth $560,000. State Street Corp grew its stake in shares of Pyxis Oncology by 28.0% during the third quarter. State Street Corp now owns 951,251 shares of the company’s stock worth $3,491,000 after purchasing an additional 208,344 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Pyxis Oncology during the fourth quarter worth $228,000. 39.09% of the stock is owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.